Karyopharm Therapeutics

Karyopharm Therapeutics(KPTI)

NEWTON, MA
Biotechnology1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules

Karyopharm Therapeutics is a life sciences company focused on Small Molecules.

OncologyHematology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT07215832Karyopharm Expanded Access Program for Selinexor
N/A
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression
Polycythemia Vera
N/A
Clinical Trials (1)
NCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
N/A
Phase 1
Clinical Trials (1)
NCT02303392Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02091245Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Phase 1
Phase 1
Clinical Trials (1)
NCT05093608SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
Phase 1
KCP-330
Sarcoma
Phase 1
Clinical Trials (1)
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Phase 1
Selinexor
Leukemia
Phase 1
Clinical Trials (1)
NCT02403310A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
Phase 1
Phase 1
Clinical Trials (1)
NCT02299518Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Selinexor
Liposarcoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02741388A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Phase 1
KPT-9274
Solid Tumors
Phase 1
Clinical Trials (1)
NCT02702492PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Phase 1
Phase 1
Clinical Trials (1)
NCT04519476Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Phase 1
Phase 1
Clinical Trials (1)
NCT02384850Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT02212561Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Phase 1
Phase 1
Clinical Trials (1)
NCT02471911KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT02120222Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
Phase 1
Selinexor
Solid Tumor
Phase 1
Clinical Trials (1)
NCT01607905Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT01607892Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1
Phase 1
Selinexor
Amyloid
Phase 1
Clinical Trials (1)
NCT04984330Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Phase 1
Phase 1
Clinical Trials (1)
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase 1
Verdinexor
Healthy
Phase 1
Clinical Trials (1)
NCT02431364Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
Phase 1
Phase 1
Clinical Trials (1)
NCT04914845KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT02078349Phase I Study of KPT330 in Asian Patients
Phase 1
Phase 1
Clinical Trials (1)
NCT03042819Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
Phase 1
Phase 1
Clinical Trials (1)
NCT02831686A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Phase 1
standard dose pelvic radiation therapy
Rectal Neoplasms
Phase 1
Clinical Trials (1)
NCT02137356Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT07200102Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT02093403Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02416908Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02367690Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT03095612Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Phase 1/2
Abemaciclib, dexamethasone, ixazomib, pomalidomide
Relapsed Refractory Multiple Myeloma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02186834Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Phase 1/2
Phase 1/2
Cyclophosphamide
Myeloma Multiple
Phase 1/2
Clinical Trials (1)
NCT03191981Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02780609Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02536495Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
Phase 1/2
Selinexor
Leukemia
Phase 1/2
Clinical Trials (1)
NCT02530476Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04856189Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05177276Selinexor Combination Ph 1 Study
Phase 1/2
Selinexor 60 MG
Multiple Myeloma
Phase 2
Clinical Trials (1)
NCT04661137A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Phase 2
Pacritinib
Myelofibrosis
Phase 2
Clinical Trials (1)
NCT07447817Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Phase 2
Selinexor
Myelofibrosis
Phase 2
Clinical Trials (1)
NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2021
Portfolio: 45 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available

Financials (FY2025)

Revenue
$146M7%
R&D Spend
$139M(95%)7%
Net Income
-$143M
Cash
$52M
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub